Dr Shaji Kumar, one of our Editors-in-Chief for touchREVIEWS in Oncology & Haematology, discusses his presentation at the 63rd ASH Annual Meeting & Exposition on the final overall survival results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Intro: 00:12-00:18
Questions
1. Could you tell us a little about the BELLINI clinical trial and the findings of the primary data analysis? 00:10-01:05
2. What were the efficacy and safety findings of the final overall survival (OS) data analysis? 01:06-04:55
3. Given the increased mortality in the treatment group, what were the conclusions of the investigators regarding the benefit-risk profile of the combination venetoclax, bortezomib and dexamethasone? 04:55-06:21
4. Which patients are most likely to benefit from this combined therapy? 06:21-07:41
5. What questions remain unanswered and what further studies are planned or ongoing? 07:41-09:00
Speaker Disclosure: Shaji Kumar discloses research funding for clinical trials to the institution from: Abbvie, Amgen, BMS, Carsgen, Janssen, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio and Molecular Templates; Consulting/Advisory Board participation (with no personal payments) from: Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secura Biotherapeutics, Monterosa therapeutics, Trillium and (with personal payment) Oncopeptides, Beigene, Antengene and GLH Pharma.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 63rd ASH Annual Meeting & Exposition
